Biggest News Aggregation in the World
📰 Slate Development News

Slate Development News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Slate Development. Real-time updates on events, politics, business and more.

Accelerated Approvals Withdrawn for Ibrutinib in Mantle Cell Lymphoma, Marginal Zone Lymphoma

Accelerated approvals for ibrutinib (Imbruvica) for patients with mantle cell lymphoma and with marginal zone lymphoma voluntarily withdrawn based on data that were insufficient to support conversion to full approval.
United States Craig Tendler Roopal Thakkar Janssen Research Development Global Medical Affairs Janssen Pharmaceutical Companies Of Johnson

Johnson & Johnson : New Results from the Phase 3 GLOW Study of Fixed-Duration Treatment with IMBRUVICA® (ibrutinib) Plus Venetoclax Demonstrate Robust Efficacy and Sustained Response in Older, Unfit Patients with Previously Untreated Chronic Lymphocytic Leukemia

NEW ORLEANS, December 10, 2022 - The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new four-year follow-up results from the Phase 3 GLOW study , which... | December 10, 2022
United States Craig Tendler Obinutuzumab Clb Carsten Niemann Christie Corbett None Of The Janssen Pharmaceutical Companies

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science